Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue

Jyoti Roy; Karson S. Putt; Domenico Coppola; Marino E. Leon; Farah K. Khalil; Barbara A. Centeno; Noel Clark; Valerie E. Stark; David L. Morse; Philip S. Low

doi:10.18632/oncotarget.28699

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue

PDF | Supplementary Files | How to cite

Oncotarget. 2025; 16:132-132. https://doi.org/10.18632/oncotarget.28699

Metrics: PDF 348 views | ?

Jyoti Roy^1,2, Karson S. Putt¹, Domenico Coppola³, Marino E. Leon³, Farah K. Khalil³, Barbara A. Centeno³, Noel Clark⁴, Valerie E. Stark⁵, David L. Morse⁵ and Philip S. Low^1,2

¹Center for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA
²Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA
³Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA
⁴Tissue Core, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA
⁵Department of Cancer Imaging and Metabolism, Imaging and Technology Center of Excellence, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA

Published: March 5, 2025

Copyright: © 2025 Roy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The Supplementary Material file has been added to this article.

Original article: Oncotarget. 2016; 7:14605–14615. DOI: https://doi.org/10.18632/oncotarget.7522.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28699

Publication Alerts

Oncoscience

Post-Publication Promotion

Addendum:

Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue